References
- Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;1:41–7
- Thessaloniki ESHRE/ASRM-sponsored PCOS consensus workshop group. Hum Reprod 2008;23:462–77
- Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139–46
- Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006;85:436–40
- Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group2. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012;27:14–24
- Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97:28–38
- Bird ST, Pepe SR, Etminan M, et al. The association between drospirenone and hyperkalemia. BMC Clin Pharmacol 2011;11:23 . doi: 10.1186/1472-6904-11-23
- Etminan M, Delaney JA, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011;183:899–904
- IMS Health. LifeLink health plan claims database: overview and study design issues. University of Arkansas for Medical Sciences; 2010. Available from: http://www.uams.edu/TRI/hsrcore/Lifelink_Health_Plan_Claims_Data_DesignIssues_wcost_April2010[1].pdf [last accessed 10 Oct 2011]
- Yaz [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2010
- Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004;27:1001–18
- Jick SS Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using united States claims data. BMJ 2011;342: doi:10.1136/bmj.d2151
- Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343:doi:10.1136/bmj.d6423 [published online ahead of print 25 October 2011]
- Van Hylckama V, Helmerhorst FM, Vanderbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA study. BMJ 2009;339: doi:10.1136/bmj.b2921
- Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2012 [Epub ahead of print]